EntryPoint Capital’s Novartis NVS Stock Holding History

EntryPoint Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-542	Closed	-$52.4K	–	1400
2024 Q1	$52.4K	Sell	542 -458	-46%	-$47K	0.05%	740
2023 Q4	$101K	Buy	+1,000	New	+$96.5K	0.1%	376

Other funds holding NVS

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Cullen Capital Management New York $9.75B AUM 21.81% 1-Year Est. Return

EntryPoint Capital's NVS Position: Q2 2024 in Review

EntryPoint Capital sold out of Novartis (NVS) in Q2 2024, closing a stake of 542 shares — an estimated $52.4K sold.

EntryPoint Capital first reported a position in NVS in Q4 2023 and held it in 2 quarters. The position peaked at $101K in Q4 2023. 1,306 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

EntryPoint Capital reported no remaining Novartis position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 542 Novartis shares in Q2 2024, an estimated $52.4K.
EntryPoint Capital first reported a position in Novartis in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's Novartis position peaked at $101K in Q4 2023.
1,306 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.